I placebogruppen fik 818 patienter hjertesvigt eller døde (38, 6%) i sammenligning med 630 i enalaprilgruppen (29, 8%) (risikoreduktion:
In the placebo group, 818 patients had heart failure or died (38.6%) as compared with 630 in the enalapril group (29.8%) (risk reduction: